Exicure technology shows effective antitumor activity in mouse tumor
models
SKOKIE, Ill.--(BUSINESS WIRE)--Oct. 1, 2018--
Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing three-dimensional, spherical nucleic
acid (SNA™) constructs, presented data in a poster session on Sunday,
September 30 at the 4th CRI-CIMT-EATI-AACR International
Immunotherapy Conference: Translating Science into Survival in New York,
New York.
The poster titled “AST-008, a novel TLR9 agonist SNA, induces
abscopal antitumor effects in mouse tumor models” supports the
ongoing clinical development of the Company's proprietary SNA™
technology and highlights new data showing the effects of Exicure’s
technology on mouse tumor models through a systemic immune response.
These data presented in the poster session show that both subcutaneous
and intra-tumoral administration of AST-008 into one tumor lesion in the
mouse model leads to systemic antitumor activity at a distant,
un-injected tumor.
“These new data, along with data from other pre-clinical tumor model
studies in combination with an anti-PD-1 antibody, and our recently
completed Phase 1 trial support the continued advancement of Exicure's
drug candidate AST-008,” said Dr. David Giljohann, Chief Executive
Officer of Exicure. “We intend to launch our Phase 1b/2 clinical trial
in combination with a checkpoint inhibitor in Q4 of 2018.”
About Exicure, Inc.
Exicure, Inc. is a clinical stage biotechnology company developing a new
class of immunomodulatory and gene regulating drugs against validated
targets. Exicure's proprietary 3-dimensional, spherical nucleic acid
spherical nucleic acid (SNA™) architecture is designed to unlock the
potential of therapeutic oligonucleotides in a wide range of cells and
tissues. Exicure's lead programs address inflammatory diseases, genetic
disorders and oncology. Exicure is based outside of Chicago, IL.www.exicuretx.com
Forward-Looking Statements
This press release contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange Act
of 1934, as amended, and Section 27A of the United States Securities Act
of 1933, as amended) concerning the Company, the Company’s technology,
potential therapies and other matters. Forward-looking statements
generally include statements that are predictive in nature and depend
upon or refer to future events or conditions, and include words such as
“may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,”
“look forward,” and other similar expressions among others. Statements
that are not historical facts are forward-looking statements.
Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of
future performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: unexpected costs, charges or
expenses that reduce cash runway; that Exicure’s pre-clinical programs
do not advance into the clinic or result in approved products on a
timely or cost effective basis or at all; the cost, timing and results
of pre-clinical and clinical trials; possible safety and efficacy
concerns; regulatory developments; and the ability of Exicure to protect
its intellectual property rights. Exicure’s pipeline programs are in
various stages of pre-clinical and clinical development, and the process
by which such pre-clinical or clinical therapeutic candidates could
potentially lead to an approved therapeutic is long and subject to
significant risks and uncertainties. Risks facing the Company and its
programs are set forth in the Company’s filings with the SEC. Except as
required by applicable law, the Company undertakes no obligation to
revise or update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181001005207/en/
Source: Exicure, Inc.
MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
or
The
Del Mar Consulting Group, Inc.
Robert Prag, 858-794-9500
President
bprag@delmarconsulting.com